Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Inovio Pharmaceuticals, Inc. - Common Stock
(NQ:
INO
)
1.810
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inovio Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Inovio Pharmaceuticals (INO) Q1 2023 Earnings Call Transcript
↗
May 11, 2023
INO earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Inovio Pharmaceuticals: Q1 Earnings Insights
↗
May 10, 2023
Via
Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
↗
April 17, 2023
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.
Via
The Motley Fool
Why Inovio Pharmaceuticals' Shares Jumped on Thursday
↗
April 13, 2023
The company will present an abstract for its Ebola vaccine booster this month.
Via
The Motley Fool
Why Shares of Inovio Pharmaceuticals Were Down Tuesday
↗
April 04, 2023
The biotech stock, still reeling from a failed clinical trial, hit a 52-week low.
Via
The Motley Fool
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
March 10, 2023
We're starting the final day of the week with a breakdown of the biggest pre-market stock movers worth watching on Friday!
Via
InvestorPlace
Earnings Scheduled For March 1, 2023
↗
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Inovio Pharmaceuticals (INO) Q3 2022 Earnings Call Transcript
↗
November 08, 2022
INO earnings call for the period ending September 30, 2022.
Via
The Motley Fool
Stocks That Hit 52-Week Lows On Monday
↗
April 03, 2023
On Monday, 76 companies set new 52-week lows.
Via
Benzinga
Inovio Pharmaceuticals (INO) Q4 2022 Earnings Call Transcript
↗
March 01, 2023
INO earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Why Inovio (INO) Shares Are Moving After-Hours
↗
March 01, 2023
After falling initially in after-hours trading on Wednesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are back up following the company report of worse-than-expected fourth-quarter financial...
Via
Benzinga
2 Stocks to Sell or Remove From Your Watchlist in 2023
↗
February 28, 2023
Both stocks soared during the coronavirus vaccine race, but their time has passed.
Via
The Motley Fool
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
February 28, 2023
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Via
FinancialNewsMedia
Inovio Pharma Releases Favorable Data From Booster DNA Vaccine Candidate For Ebola
↗
February 02, 2023
Inovio Pharmaceuticals Inc (NASDAQ: INO) announced results from a Phase 1b trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a...
Via
Benzinga
3 Sorry Pharma Stocks to Sell in February Before It’s Too Late
↗
February 01, 2023
These are the pharma stocks to sell, as they represent companies with weak fundamentals and sustained cash burn visibility.
Via
InvestorPlace
INOVIO Announces Further Reorganization, Continues Focus on Promising DNA Candidates
↗
January 31, 2023
Via
Benzinga
If You Invested $1,000 In Inovio Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now
↗
January 10, 2023
Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two and a half years. But there was no question some big-name stocks performed...
Via
Benzinga
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
↗
December 30, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Micron, Lexicon Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
↗
December 22, 2022
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Westrock Coffee Company, LLC (NASDAQ: WEST) shares tumbled 10.9% to $11.90...
Via
Benzinga
Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket
↗
December 20, 2022
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small...
Via
Benzinga
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket
↗
December 19, 2022
Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM ImmunoTech recently reported safety, tolerability and biological activity data for intranasal ampligen in...
Via
Benzinga
Within A Month After Pulling Plug On COVID-19 Booster Study, Inovio Shelves Two More Infectious Disease Programs
↗
November 18, 2022
Via
Benzinga
3 Stocks to Avoid Right Now
↗
November 17, 2022
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
Via
The Motley Fool
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
November 16, 2022
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Why Inovio Pharmaceuticals Stock Is Popping Off
↗
November 09, 2022
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher by 9.11% to $2.34 after the company reported third-quarter financi
Via
Benzinga
What's Going On With Inovio Pharmaceuticals Stock Tuesday After Hours
↗
November 08, 2022
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading marginally lower by 0.93% to $2.12 after the company reported
Via
Benzinga
Threats For New Outbreak Looms, As Scientists Signal Deadly Monkeypox Variant Circulating In Central Africa
↗
November 03, 2022
Researchers have warned that a dangerous monkeypox variant with a fatality rate as high as 10% is circulating in Central Africa, which could trigger new global outbreaks. After analyzing 1,463 cases...
Via
Benzinga
Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today
↗
October 28, 2022
The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster.
Via
The Motley Fool
Inovio Pharma Stops Work On INO-4800 As COVID-19 Heterologous Booster
↗
October 28, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
↗
November 01, 2022
Upgrades
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today